Encephalitis News and Research

Latest Encephalitis News and Research

Sinovac first quarter sales increase 30.3% to $6.0M

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today its unaudited first quarter financial results for the period ended March 31, 2012.

15 May 2012

Repeated blows to the head associated with long term cognitive, pathologic changes

NFL great Junior Seau's apparent suicide might shock the sports world, but to neurosurgeons and neurologists accustomed to seeing an increase in the incidence of concussions, especially among football players, the news isn't as surprising.

3 May 2012

Europe becoming 'hotspot' for emerging infections, study suggests

"Europe is becoming a 'hotspot' for emerging infections as those typically confined to tropical climates are making their way north, according to research that links climate change to the global spread of disease," the Financial Times reports.

3 May 2012

New global strategy to reduce measles deaths and congenital rubella syndrome

Today, the partners leading efforts to control measles announce a new global strategy aimed at reducing measles deaths and congenital rubella syndrome to zero.

2 May 2012

Bats may be a common source of many viral diseases

Where do viruses dangerous to humans come from, and how have they evolved? Scientists working with Prof. Dr. Christian Drosten, Head of the In-stitute for Virology at the Universit-tsklinikum Bonn, have made significant progress in answering this question. "We already knew from prior studies that bats and rodents play a role as carriers of paramyxoviruses," said Prof. Drosten.

25 Apr 2012

Herpes zoster vaccine safe and well tolerated: Study

The herpes zoster vaccine, also known as the shingles vaccine, is generally safe and well tolerated according to a Vaccine Safety Datalink study of 193,083 adults published online in the Journal of Internal Medicine.

23 Apr 2012

First treatment guidelines for NMDA-receptor encephalitis

A mysterious, difficult-to-diagnose, and potentially deadly disease that was only recently discovered can be controlled most effectively if treatment is started within the first month that symptoms occur, according to a new report by researchers from the Perelman School of Medicine at the University of Pennsylvania.

21 Apr 2012

Computer model can predict malaria epidemics in India

Scientists from the University of Liverpool are working with computer modelling specialists in India to predict areas of the country that are at most risk of malaria outbreaks, following changes in monsoon rainfall.

3 Apr 2012

Epilepsy community welcomes IOM's new landmark study report

Responding to today's release of the Institute of Medicine 's (IOM) new report on the public health dimensions of the epilepsies, a cooperative group of professional and consumer organizations with special interest in epilepsy has issued the following joint statement.

31 Mar 2012

New report highlights numerous gaps in knowledge and management of epilepsy

A new report from the Institute of Medicine highlights numerous gaps in the knowledge and management of epilepsy and recommends actions for improving the lives of those with epilepsy and their families and promoting better understanding of the disorder.

31 Mar 2012

Broad-ranging CVBD prevention key element of animal health planning

As part of its ongoing commitment to the scientific community, Bayer Animal Health today marked their seventh year of support for the CVBD World Forum (CVBD7) in Berlin, Germany; and this year's meeting has again proven to be a landmark in the understanding of CVBDs.

29 Mar 2012

Top-line results from Inviragen's INV21 Phase 1 trial on HFMD

Inviragen today reported top-line results of a placebo-controlled, randomized Phase 1 trial of INV21, the Company's highly purified virus particle vaccine against Hand, Foot and Mouth Disease (HFMD) caused by enterovirus 71.

12 Mar 2012

Critical new details about structure of enterovirus 71

Researchers have discovered critical new details about the structure of a virus that causes potentially fatal brain swelling and paralysis in children, pointing toward designs for antiviral drugs to treat the disease.

3 Mar 2012

USPTO issues two patents on 'Novel Shigella protein antigens and methods' to IVI

The International Vaccine Institute (IVI), an international organization based in Seoul devoted to research on the development and introduction of vaccines for the developing world, reached a milestone in its aim to prevent and control dysentery (also commonly called shigellosis or bloody diarrhea), a deadly disease that affects several million people worldwide.

27 Feb 2012

Cedars-Sinai scientist to study potential treatments for AD

A Cedars-Sinai research scientist has been awarded two national grants totaling more than $2.5 million, including a prestigious Research Project Grant from the National Institutes of Health to study potential treatments for Alzheimer's disease.

21 Feb 2012

Exercise fails to improve glucose metabolism in autophagy-deficient mice

The health benefits of exercise on blood sugar metabolism may come from the body's ability to devour itself, UT Southwestern Medical Center researchers report in the journal Nature.

21 Jan 2012

Shortages of anti-infective drugs can put patients at risk and alter clinical care

Shortages of key drugs used to fight infections represent a public health emergency and can put patients at risk, according to a review published in Clinical Infectious Diseases and available online.

20 Jan 2012

Mosquito borne Murray Valley Encephalitis warnings for NSW and North Victoria

The NSW Health authorities are warning residents and visitors in southern and western NSW to take extra precautions and protect themselves against mosquitoes following the detection of the Murray Valley Encephalitis (or MVE) virus in NSW. Residents and visitors to North Victoria are also similarly warned.

1 Jan 2012

Experimental sublingual vaccine shows promise against influenza infection

Scientists from the International Vaccine Institute (IVI) have discovered that an antigen common to most influenza viruses, and commonly referred to as matrix protein 2 (M2), when administered under the tongue could protect mice against experimental infection caused by various influenza viruses, including the highly pathogenic avian H5 virus and the pandemic H1 ("swine flu") virus.

9 Dec 2011

Inviragen presents DENVax Phase 1 trial results on dengue at ASTMH annual meeting

Inviragen, Inc. presented results of the Phase 1 clinical trial of DENVax conducted in Colombia at the annual American Society of Tropical Medicine and Hygiene (ASTMH) meeting today.

8 Dec 2011